# Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

> **NCT02807805** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mamta Parikh** · enrollment: 37 (actual)

## Conditions studied

- Metastatic Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Niclosamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02807805
- **Lead sponsor:** Mamta Parikh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02807805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02807805, "Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02807805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*